NeoGenomics Raises Guidance and Projects 30% Year-Over-Year Revenue Growth in Quarter 2, 2014

Company Experiencing Strong Test Volume Growth

FT. MYERS, Fla., June 23, 2014 -- NeoGenomics, Inc. (NEO),a leading provider of cancer-focused genetic testing services, announced today that it was raising its previously issued revenue guidance for Quarter 2, 2014.  The Company now expects revenue of approximately $20.0 - $20.5 million for the second quarter of 2014 compared with its previous estimate of $18.8 - $19.3 million.  The Company also reaffirmed its previously issued earnings per share guidance of $0.00 - $0.01 for the quarter.   

Doug VanOort, the Company's Chairman and CEO, commented, "We experienced exceptionally strong year-over-year volume growth in April and May driven by a continued increase in the number of new customer accounts.

Published: 23 June 2014
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: NeoGenomics Inc ( NEO )

BioReference Laboratories, Inc. Reports Record Quarterly Revenues and Patient Volumes for Second Quarter FY2014

Quarterly Revenues and Patient Volumes Both Increased by Over 14%, Cash Flow Returned to Positive

ELMWOOD PARK, N.J., June 5, 2014 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc. (BRLI) announces record second quarter results for revenues and patient volumes. Except for per share data or where otherwise noted, numbers are in thousands.

The Company recorded Q2FY14 revenues of $201,366, the highest recorded revenues in a quarter in corporate history, representing an increase of 14% over the $176,452 recorded in Q2FY13 despite the adverse effects of weather during the quarter that resulted in a reduction of revenue that the Company estimates at $5,000. Operating income for Q2FY14 was $18,879, down 9% from the Q2FY13 operating income of $20,709.

Published: 05 June 2014
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: BioReference Laboratories Inc ( BRLI )

New York, NY - Point Roberts, WA - April 15, 2014 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, global news source covering leading sectors including food and beverage and LOHAS (Lifestyles of Health and Sustainability) issues an alert on the global trend of rising stevia sales.

As health concerns of too much sugar continue to make headlines, diehard sugar fans like The Coca-Cola Company ( NYSE:KO ) and PepsiCo NYSE:PEP ) continue to push international sales of sugary sodas. However, a trend towards healthier alternatives such as stevia continue to be reflected in the increased sales of stevia makers GLG Life Tech Corporation (TSX: GLG), (OTC: GLGLF) and PureCircle Limited (LSE:PURE.L).

A global battle about health and sustainability is brewing between vegans and the meat industry, and the sugar and stevia industries. According to the Global Stevia Institute, "Stevia's great tasting, zero-calorie sweetness not only can be part of a healthful diet, it can be part of a more environmentally friendly diet too.”

Published: 15 April 2014
Written by Investor Ideas
Submitted News  
Read more: The Global Race for Consumer Taste: Sugar vs. Stevia; PepsiCo (PEP), Coca-Cola (KO), GLG Life Tech...

Subcategories

Pharmaceuticals

Medical Laboratories & Research